Self and Autobiographical Memory in Dementia With Lewy Bodies and Alzheimer Disease: a Behavioral and Multimodal Neuroimaging Study

NCT ID: NCT04616287

Last Updated: 2025-10-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-25

Study Completion Date

2023-10-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present project aims at exploring different components of Self-consciousness or 'the Self', such as autobiographical memory, self-concept and subjective sense of Self, in dementia with Lewy Bodies (DLB) compared to Alzheimer's disease and to normal ageing. Anatomical substrates will be studied in multimodal imaging, in terms of volume, anatomical and functional connectivity. We expect to find an alteration of the different components of the Self, consecutive to insular dysfunction, a key region within cerebral networks of self-consciousness, which is damaged early in the course of the disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dementia With Lewy Bodies Alzheimer Disease Self Autobiographical Memory Insular Cortex

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dementia with Lewy bodies

Group Type EXPERIMENTAL

Neuropsychological assessment and Multimodal brain MRI

Intervention Type OTHER

Neuropsychological assessment and Multimodal brain MRI

Alzheimer disease

Group Type ACTIVE_COMPARATOR

Neuropsychological assessment and Multimodal brain MRI

Intervention Type OTHER

Neuropsychological assessment and Multimodal brain MRI

healthy elderly subjects

Group Type SHAM_COMPARATOR

Neuropsychological assessment and Multimodal brain MRI

Intervention Type OTHER

Neuropsychological assessment and Multimodal brain MRI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neuropsychological assessment and Multimodal brain MRI

Neuropsychological assessment and Multimodal brain MRI

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged between 60 to 80, at the inclusion visit
* Right-handed
* Must be affiliated to a social health insurance protection scheme
* Must be able both to understand the objectives and risks related to the study and to give a dated and signed informed consent
* Fluency in French
* At least 9 years of formal education


* Subject meeting McKeith et al. criteria (2017)
* Subject with prodromal dementia with Lewy bodies meeting the DSM-V Mild Cognitive Impairment criteria (2013)
* Subject with prodromal or mild dementia with Lewy bodies with an ≤ 20 MMSE score
* Availability of a caregiver for the inclusion visit


* Subject meeting Dubois et al. criteria (2014)
* Subject with prodromal or mild Alzheimer disease with an ≤ 20 MMSE score
* Availability of a caregiver for the inclusion visit


* Subject must be matched with patients in terms of age, gender and educational level
* Absence of any cognitive complaint
* Autonomy must be preserved

Exclusion Criteria

Subjects with significant neuropsychiatric comorbidities

* Abnormal neurological examination
* Sensory impairment that may significantly interfere with testing
* Contraindication to MRI
* Claustrophobia
* Heavy psychotropic drug treatment
* Excessive and regular consumption of alcohol
* Subject in period of exclusion (determined by a previous or ongoing study)
* Inability to give the subject informed information
* Subject under judicial protection
* Subject under tutorship or guardianship
Minimum Eligible Age

60 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nathalie PHILIPPI, MD

Role: PRINCIPAL_INVESTIGATOR

Hôpitaux Universitaires de Strasbourg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpitaux Universitaires de Strasbourg

Strasbourg, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Tisserand A, Philippi N, Botzung A, Blanc F. Me, Myself and My Insula: An Oasis in the Forefront of Self-Consciousness. Biology (Basel). 2023 Apr 14;12(4):599. doi: 10.3390/biology12040599.

Reference Type BACKGROUND
PMID: 37106799 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

7942

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.